Today: 9 November 2025
Subscribe
Browse Category

Pharma Industry News 22 October 2025 - 7 November 2025

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Last updated: Nov 7, 2025 (19:23 UTC) Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print, the stock’s day range was $24.12–$24.61 on heavy volume. Key takeaways Pfizer stock price today (intraday) What changed today — Nov 7, 2025 1) Metsera bidding war heats up Why it matters: The Metsera outcome could reshape Pfizer’s cardiometabolic/obesity ambitions after earlier setbacks, and investors are repricing PFE daily on any signal of who ultimately wins—and at what cost. Financial
7 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven by two big headlines: (1) a White House pricing agreement that expands access to GLP‑1 drugs across Medicare/Medicaid and a new direct‑to‑consumer channel, and (2) a $10 billion bidding battle with Pfizer for obesity‑drug startup Metsera. What changed today 1) White House pricing deal lowers GLP‑1 costs and expands coverage The administration announced a deal with Novo Nordisk and Eli
6 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged prnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4 reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Company Profile & Background Scienture Holdings, Inc. is a tiny specialty pharmaceutical company focused on developing and commercializing novel formulations that address unmet needs in healthcare globenewswire.com globenewswire.com. The company’s roots trace back to a 2024 merger with TRxADE Health, a drug marketplace business – after which the combined entity rebranded as Scienture (NASDAQ: SCNX) nasdaq.com. In early 2025, management decisively pivoted to pharma: selling off legacy pharmacy/IT subsidiaries for $5 million to free up resources and “dedicate full focus” to its specialty drug pipeline globenewswire.com globenewswire.com. Today Scienture is headquartered in Tampa, FL (with R&D operations in New York)
4 November 2025
 ·  ·  ·  · 
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Stock Price and Recent Performance Year-to-date chart of Evoke Pharma (EVOK) stock through early November 2025. Shares were volatile throughout 2025, and the Q4 acquisition announcement (right end of chart) triggered a dramatic spike to new highs, bringing the stock roughly back to breakeven for the year tipranks.com. Evoke Pharma’s stock has experienced extreme volatility in recent weeks. After trading in the mid-$4 to $5 range through October, EVOK plunged 10.9% on November 3, 2025 to $4.59 at the close tipranks.com. The very next day, news of the buyout sent the stock exploding upward – EVOK opened around $10.70 on
4 November 2025
 ·  ·  ·  ·  · 
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir Surges on Strong AI-Fueled Earnings Palantir Technologies delivered a record third quarter, easily topping analyst expectations on both revenue and profit. The company’s revenue jumped 63% year-over-year to $1.18 billion, with adjusted earnings of $0.21 per share – well above estimates of about $0.17 investopedia.com. CEO Alex Karp credited booming demand for Palantir’s Artificial Intelligence Platform, especially among commercial customers. U.S. commercial revenue more than doubled (+121% YoY) to $397 million, outpacing even robust growth in government contracts investopedia.com. Karp hailed the commercial business as an “absolute juggernaut” and lauded the company’s “otherworldly” AI-driven growth in a letter to investors investopedia.com.
4 November 2025
 ·  ·  ·  ·  · 
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that month reuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels. However, in the past few days the stock’s momentum sharply reversed. On Monday, Nov 3,
3 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably, PFE is trading below its 200-day moving average (~$27), indicating lingering bearish momentum trefis.com. On the upside, a decisive push above the $27–$28 level (and the 200-day MA) would be a bullish signal that the stock’s trend is turning. In
1 November 2025
 ·  ·  ·  ·  · 
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR therapy NTLA-2001 due to a serious adverse event ts2.tech. The immediate market reaction was brutal: NTLA stock plunged ~44% in pre-market trading and went on to close around $14.79 (down roughly 42% for the day) ts2.tech marketbeat.com. In dollar terms, shares that traded near $25–26 late last week collapsed into
28 October 2025
 ·  ·  ·  ·  · 
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to the company and press accounts, the trial met its primary endpoint with a statistically significant jump in progression-free survival (PFS) biospace.com. Patients on ozekibart lived a median 5.52 months without progression versus 2.66 months on placebo – a 52% reduction in the risk of progression or death biospace.com. All patient subgroups (including those with or without IDH mutations) saw benefit,
24 October 2025
 ·  ·  ·  ·  · 
Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year marketbeat.com – following stronger-than-expected Q2 results (earnings beat and record revenue). However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that ARCT fell about 50% as investors digested the mixed news ng.investing.com. By pre-market trading the next day it was down over 60% at roughly $9 benzinga.com. MarketBeat confirmed that Guggenheim downgraded the stock to Neutral on Oct 22 marketbeat.com. Overall,
22 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop